Hargreaves Lansdown

Silence Therapeutics begins dosing in lipoprotein treatment trial

Wed 17 February 2021 08:12 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Silence Therapeutics has started dosing subjects in the 'APOLLO' phase 1 clinical study of its wholly-owned lead product candidate 'SLN360', it announced on Wednesday, for the treatment of elevated lipoprotein-a (Lp(a)) levels.

The AIM-traded firm said the first-in-human study was investigating the safety, tolerability, pharmacokinetic and pharmacodynamic response of SLN360 in people with elevated Lp(a) levels of at least 60 milligrams per decilitre.

"The APOLLO trial is a global, randomized, double-blind, placebo controlled, single-ascending and multiple-ascending dose study enrolling approximately 88 subjects total in up to nine cohorts," the Silence board explained in its statement.

The company said it intended to report data from the single-ascending dose portion of the study in the second half of the year.

At 1044 GMT, shares in Silence Therapeutics were down 1.32% at 600p.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.

    More AIM news from ShareCast

    No results were found